SCHEMBL10224751

SCHEMBL10224751

CC(=O)NCCNc1nccc(C(C)(C)C)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.46
CYP3A4 P08684 3/20 0.44
HSD17B10 Q99714 3/20 0.44
CYP1A2 P05177 3/20 0.44
CLK4 Q9HAZ1 3/20 0.44
ALDH1A1 P00352 2/20 0.44
ALOX15 P16050 2/20 0.44
MAPK1 P28482 1/20 0.44
PKM P14618 1/20 0.42
CA12 O43570 1/20 0.40
CA4 P22748 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
SYK P43405 6/20 0.40
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
MTNR1A P48039 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10225052 0.81 CYP1A2 (0.50) CYP3A4HSD17B10CYP1A2CLK4ALDH1A1
SCHEMBL15181300 0.79 SYK (0.44) PLK1ALDH1A1PKMCA9SYK
SCHEMBL91325 0.78 CYP1A2 (0.45) CYP3A4HSD17B10CYP1A2CLK4ALDH1A1
SCHEMBL84366 0.77 CYP1A2 (0.44) CYP3A4HSD17B10CYP1A2CLK4ALDH1A1
SCHEMBL25056999 0.76 ALDH1A1 (0.61) CYP3A4HSD17B10CYP1A2CLK4ALDH1A1
SCHEMBL11988199 0.76 HRH4 (0.52) PLK1PKMCA9SYKHRH4
SCHEMBL24650717 0.75 MKNK1 (0.48) PLK1CYP3A4HSD17B10CYP1A2CLK4
SCHEMBL16844971 0.73 HRH4 (0.52) SYKHRH4HRH3
SCHEMBL1089291 0.73 CXCR4 (0.64) ALDH1A1HRH4HRH3
SCHEMBL11988630 0.72 EIF2AK2 (0.48) PLK1HSD17B10ALDH1A1MAPK1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS PLK1 62/4885CYP3A4 4401/4885HSD17B10 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.